SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of March 2018

Commission File Number 001-38068

Zymeworks Inc.

(Translation of registrant’s name into English)

Suite 540, 1385 West 8^th Avenue, Vancouver, British Columbia, Canada, V6H 3V9

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

EXHIBITS INCLUDED AS PART OF THIS REPORT

Exhibit
99.1	Press Release – Zymeworks to Present at Barclays 2018 Global Healthcare Conference
99.2	Material Change Report – Zymeworks Opening Clinical Sites in Canada
99.3	Material Change Report – Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ZYMEWORKS INC.
		(Registrant)
Date: March 7, 2018		By:	/s/ Neil Klompas
		Name: Title:	Neil Klompas Chief Financial Officer